1
|
Siegel R, DeSantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Wei EK, Giovannucci E, Wu K, Rosner B,
Fuchs CS, Willett WC and Colditz GA: Comparison of risk factors for
colon and rectal cancer. Int J Cancer. 108:433–442. 2004.
View Article : Google Scholar
|
3
|
Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B,
van Krieken JHJ, et al: Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J
Med. 345:638–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cammà C, Giunta M, Fiorica F, Pagliaro L,
Craxì A and Cottone M: Preoperative radiotherapy for resectable
rectal cancer: A meta-analysis. JAMA. 284:1008–1015. 2000.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Schmiegel W, Pox C, Reinacher-Schick A,
Adler G, Fleig W, Fçlsch U, Frühmorgen P, Graeven U, Hohenberger W,
Holstege A, et al: S3-Leitlinie, Kolorektales Karzinom Ergebnisse
evidenzbasierter Konsensuskonferenzen am 6./7. Februar 2004 und am
8./9. Juni 2007 (für die Themenkomplexe IV, VI und VII). Z
Gastroenterol. 46:1–73. 2008.In German.
|
6
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo L-J, Calvo FA, García-Aguilar J, Glynne-Jones R and
Haustermans K: Long-term outcome in patients with a pathological
complete response after chemoradiation for rectal cancer: A pooled
analysis of individual patient data. Lancet Oncol. 11:835–844.
2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J colorectal dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
8
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Wittekind C and Tannapfel A:
Regressionsgrading des präoperativ-radiochemotherapierten
rektumkarzinoms. Der Pathologe. 24:61–65. 2003.In German.
|
10
|
Bomsztyk K, Denisenko O and Ostrowski J:
hnRNP K: One protein multiple processes. Bioessays. 26:629–638.
2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ostareck-Lederer A, Ostareck DH, Cans C,
Neubauer G, Bomsztyk K, Superti-Furga G and Hentze MW:
c-Src-mediated phosphorylation of hnRNP K drives translational
activation of specifically silenced mRNAs. Mol Cell Biol.
22:4535–4543. 2002. View Article : Google Scholar : PubMed/NCBI
|
12
|
Carpenter B, McKay M, Dundas S, Lawrie L,
Telfer C and Murray G: Heterogeneous nuclear ribonucleoprotein K is
over expressed, aberrantly localised and is associated with poor
prognosis in colorectal cancer. Br J Cancer. 95:921–927. 2006.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Eder S, Lamkowski A, Priller M, Port M and
Steinestel K: Radiosensitization and downregulation of
heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition
of mitogen/extracellular signal-regulated kinase (MEK) in malignant
melanoma cells. Oncotarget. 6:17178–17191. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Barboro P, Ferrari N and Balbi C: Emerging
roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in
cancer progression. Cancer Lett. 352:152–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Eder S, Arndt A, Lamkowski A, Daskalaki W,
Rump A, Priller M, Genze F, Wardelmann E, Port M and Steinestel K:
Baseline MAPK signaling activity confers intrinsic radioresistance
to KRAS-mutant colorectal carcinoma cells by rapid upregulation of
heterogeneous nuclear ribonucleoprotein K (hnRNP K). Cancer Lett.
385:160–167. 2017. View Article : Google Scholar
|
16
|
Moumen A, Masterson P, O’Connor MJ and
Jackson SP: hnRNP K: An HDM2 target and transcriptional coactivator
of p53 in response to DNA damage. Cell. 123:1065–1078. 2005.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Enge M, Bao W, Hedström E, Jackson SP,
Moumen A and Selivanova G: MDM2-dependent downregulation of p21 and
hnRNP K provides a switch between apoptosis and growth arrest
induced by pharmacologically activated p53. Cancer cell.
15:171–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Moumen A, Magill C, Dry KL and Jackson SP:
ATM-dependent phosphorylation of heterogeneous nuclear
ribonucleoprotein K promotes p53 transcriptional activation in
response to DNA damage. Cell Cycle. 12:698–704. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Shimura T, Kakuda S, Ochiai Y, Nakagawa H,
Kuwahara Y, Takai Y, Kobayashi J, Komatsu K and Fukumoto M:
Acquired radiore-sistance of human tumor cells by
DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression. Oncogene.
29:4826–4837. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bae I, Fan S, Bhatia K, Kohn KW, Fornace
AJ and O’Connor PM: Relationships between G1 arrest and
stability of the p53 and p21Cip1/Waf1 proteins following
γ-irradiation of human lymphoma cells. Cancer Res. 55:2387–2393.
1995.PubMed/NCBI
|
21
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D
and Jassem J: Panitumumab-FOLFOX4 treatment and RAS mutations in
colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Moskalev EA, Stöhr R, Rieker R, Hebele S,
Fuchs F, Sirbu H, Mastitsky SE, Boltze C, König H and Agaimy A:
Increased detection rates of EGFR and KRAS mutations in NSCLC
specimens with low tumour cell content by 454 deep sequencing.
Virchows Arch. 462:409–419. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez
MJ, Gocke CD, Eshleman JR and Murphy KM: Comparison of sanger
sequencing, pyrosequencing, and melting curve analysis for the
detection of KRAS mutations: diagnostic and clinical implications.
J Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang M, Kern AM, Hulskotter M, Greninger
P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, et
al: EGFR-mediated chromatin condensation protects KRAS-mutant
cancer cells against ionizing radiation. Cancer Res. 74:2825–2834.
2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Gupta AK, Bakanauskas VJ, Cerniglia GJ,
Cheng Y, Bernhard EJ, Muschel RJ and McKenna WG: The Ras radiation
resistance pathway. Cancer Res. 61:4278–4282. 2010.
|
27
|
Qiu W, Leibowitz B, Zhang L and Yu J:
Growth factors protect intestinal stem cells from radiation-induced
apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis.
Oncogene. 29:1622–1632. 2010. View Article : Google Scholar
|
28
|
Canman CE, Lim DS, Cimprich KA, Taya Y,
Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD:
Activation of the ATM kinase by ionizing radiation and
phosphorylation of p53. Science. 281:1677–1679. 1998. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ward IM, Wu X and Chen J: Threonine 68 of
Chk2 is phosphorylated at sites of DNA strand breaks. J Biol Chem.
276:47755–47758. 2001. View Article : Google Scholar : PubMed/NCBI
|
30
|
Chinnaiyan P, Vallabhaneni G, Armstrong E,
Huang SM and Harari PM: Modulation of radiation response by histone
deacetylase inhibition. Int J Radiat Oncol Biol Phys. 62:223–229.
2005. View Article : Google Scholar : PubMed/NCBI
|
31
|
Rochette PJ, Bastien N, Lavoie J, Guérin
SL and Drouin R: SW480, a p53 double-mutant cell line retains
proficiency for some p53 functions. J Mol Biol. 352:44–57. 2005.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Xiao Z, Ko HL, Goh EH, Wang B and Ren EC:
hnRNP K suppresses apoptosis independent of p53 status by
maintaining high levels of endogenous caspase inhibitors.
Carcinogenesis. 34:1458–1467. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Evans JR, Mitchell SA, Spriggs KA,
Ostrowski J, Bomsztyk K, Ostarek D and Willis AE: Members of the
poly (rC) binding protein family stimulate the activity of the
c-myc internal ribosome entry segment in vitro and in vivo.
Oncogene. 22:8012–8020. 2003. View Article : Google Scholar : PubMed/NCBI
|
34
|
Chen LC, Liu HP, Li HP, Hsueh C, Yu JS,
Liang CL and Chang YS: Thymidine phosphorylase mRNA stability and
protein levels are increased through ERK-mediated cytoplasmic
accumulation of hnRNP K in nasopharyngeal carcinoma cells.
Oncogene. 28:1904–1915. 2009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kim D, Kim W, Lee K, Kim S, Lee H, Kim H,
Jung Y, Choi J and Kim K: hnRNP Q regulates translation of p53 in
normal and stress conditions. Cell Death Differ. 20:226–234. 2013.
View Article : Google Scholar :
|